Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis

키워드

참고문헌 (73)

1. Collins PY, "Daar AS;Scientific Advisory Board and the Executive Committee of the Grand Challenges on Global Mental Health. Grand challenges in global mental health", Nature, 475, pp.27~30 (2011)
2. Kim YK, "A novel bio-psychosocial-behavioral treatment model in schizophrenia", Int J Mol Sci, 18, pp.E734~ (2017)
3. Filiz Karadag, "Relationship between Serum Bilirubin Levels and Metabolic Syndrome in Patients with Schizophrenia Spectrum Disorders", Clinical Psychopharmacology and Neuroscience, 15(2), pp.153~162 (2017), 대한정신약물학회[DOI]
4. Adarsh Tripathi, "Cognitive Deficits in Schizophrenia: Understanding the Biological Correlates and Remediation Strategies", Clinical Psychopharmacology and Neuroscience, 16(1), pp.7~17 (2018), 대한정신약물학회[DOI]
5. Corrigan PW, "From noncompliance to collaboration in the treatment of schizophrenia", Hosp Community Psychiatry, 41, pp.1203~1211 (1990)
6. Novick D, "Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia", Psychiatry Res, 176, pp.109~113 (2010)
7. Olfson M, "Predicting medication noncompliance after hospital discharge among patients with schizophrenia", Psychiatr Serv, 51, pp.216~222 (2000)
8. Leucht C, "Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials", Schizophr Res, 127, pp.83~92 (2011)
9. Adams CE, "Systematic meta-review of depot antipsychotic drugs for people with schizophrenia", Br J Psychiatry, 179, pp.290~299 (2001)
10. Kishimoto T, "Long-acting injectable versus oral antipsychotics in schizophrenia:a systematic review and meta-analysis of mirror-image studies", J Clin Psychiatry, 74, pp.957~965 (2013)
11. Kishimoto T, "Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials", Schizophr Bull, 40, pp.192~213 (2014)
12. Manchanda R, "Long-acting injectable antipsychotics: evidence of effectiveness and use", Can J Psychiatry, 58(5 Suppl 1), pp.5S~13S (2013)
13. Kishi T, "Mortality risk associated with long-acting injectable antipsychotics: a systematic review and meta-analyses of randomized controlled trials", Schizophr Bull, 42, pp.1438~1445 (2016)
14. Kishi T, "Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: a systematic review and meta-analysis of randomized controlled trials", Psychiatry Res, 246, pp.750~755 (2016)
15. Lafeuille MH, "Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia", Curr Med Res Opin, 30, pp.1643~1655 (2014)
16. Misawa F, "Safety and tolerability of long-acting injectable versus oral antipsychotics:A meta-analysis of randomized controlled studies comparing the same antipsychotics", Schizophr Res, 176, pp.220~230 (2016)
17. Ostuzzi G, "Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies", Schizophr Res, 183, pp.10~21 (2017)
18. Meltzer HY, "Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values", J Pharmacol Exp Ther, 251, pp.238~246 (1989)
19. Fischer-Barnicol D, "Working Group ‘Drugs in Psychiatry’. Typical and atypical antipsychotics: the misleading dichotomy. Results from the Working Group ‘Drugs in Psychiatry’(AGATE)", Neuropsychobiology, 57, pp.80~87 (2008)
20. Charych EI, "GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders", Neuropharmacology, 57, pp.481~495 (2009)
21. Gründer G, "The ‘atypicality’ of antipsychotics:a concept re-examined and re-defined", Nat Rev Drug Discov, 8, pp.197~202 (2009)
22. Kim YS, "Principle and practice of long-acting injectable antipsychotics", pp.40~41 (2010), Seoul National University Press
23. Fusar-Poli P, "Efficacy and safety of second-generation long-acting injections in schizophrenia:a meta-analysis of randomized-controlled trials", Int Clin Psychopharmacol, 28, pp.57~66 (2013)
24. Huang X, "Evaluation of PICO as a knowledge representation for clinical questions", AMIA Annu Symp Proc, pp.359~363 (2006)
25. Tandon R, "Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future", Schizophr Res, 122, pp.1~23 (2010)
26. Guy W, "ECDEU assessment manual for psychopharmacology, Revised 1976" (1976), National Institute for Mental Health
27. Kay SR, "The Positive and Negative Syndrome Scale (PANSS) for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
28. Montgomery SA, "A new depression scale designed to be sensitive to change", Br J Psychiatry, 134, pp.382~389 (1979)
29. Chouinard G, "Manual for the Extrapyramidal Symptom Rating Scale (ESRS)", Schizophr Res, 76, pp.247~265 (2005)
30. Munetz MR, "How to examine patients using the Abnormal Involuntary Movement Scale", Hosp Community Psychiatry, 39, pp.1172~1177 (1988)
31. Moher D, "PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P)2015 statement", Syst Rev, 4, pp.1~ (2015)
32. Higgins JPT, "Cochrane handbook for systematic reviews of interventions" (2008), Wiley-Blackwell
33. Kim SY, "Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity", J Clin Epidemiol, 66, pp.408~414 (2013)
34. Guyatt G, "GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables", J Clin Epidemiol, 64, pp.383~394 (2011)
35. Ascher-Svanum H, "Predictors of psychiatric hospitalization during 6months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study", BMC Psychiatry, 13, pp.224~ (2013)
36. Bai YM, "A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study", Pharmacopsychiatry, 39, pp.135~141 (2006)
37. Barrio P, "Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia:a case-control study", Int Clin Psychopharmacol, 28, pp.164~170 (2013)
38. Beauclair L, "Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia", J Med Econ, 10, pp.427~442 (2007)
39. Buckley PF, "PROACTIVE Study. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study", Schizophr Bull, 41, pp.449~459 (2015)
40. Chue P, "Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets", Eur Neuropsychopharmacol, 15, pp.111~117 (2005)
41. de Arce Cordón R, "Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)", Eur Arch Psychiatry Clin Neurosci, 262, pp.139~149 (2012)
42. Detke HC, "Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia", J Clin Psychopharmacol, 34, pp.426~434 (2014)
43. Fe Bravo-Ortiz M, "Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers", Int J Psychiatry Clin Pract, 15, pp.286~295 (2011)
44. Fleischhacker WW, "Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, noninferiority study", Br J Psychiatry, 205, pp.135~144 (2014)
45. Gaebel W, "Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial", Neuropsychopharmacology, 35, pp.2367~2377 (2010)
46. Huang SS, "Antipsychotic formulation and one-year rehospitalization of schizophrenia patients: a population-based cohort study", Psychiatr Serv, 64, pp.1259~1262 (2013)
47. Ishigooka J, "ALPHA Study Group. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole", Schizophr Res, 161, pp.421~428 (2015)
48. Keks NA, "Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study", Br J Psychiatry, 191, pp.131~139 (2007)
49. Kim B, "Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1231~1235 (2008)
50. Lang K, "Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics", Psychiatr Serv, 61, pp.1239~1247 (2010)
51. Llorca PM, "Symptom control, functioning, and hospitalization status in French patients changed from oral atypical antipsychotics to risperidone long-acting injectable", Int J Psychiatry Clin Pract, 10, pp.276~284 (2006)
52. Macfadden W, "A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia", Psychiatry (Edgmont), 7, pp.23~31 (2010)
53. McDonnell DP, "Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine", Hum Psychopharmacol, 26, pp.422~433 (2011)
54. Rouillon F, "Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)", Acta Neuropsychiatr, 25, pp.297~306 (2013)
55. Schmauss M, "Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone", Int Clin Psychopharmacol, 22, pp.85~92 (2007)
56. Schmauss M, "Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?", Pharmacopsychiatry, 43, pp.73~80 (2010)
57. Smeraldi E, "Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)", Ther Adv Psychopharmacol, 3, pp.191~199 (2013)
58. Spill B, "Long-term observation of patients successfully switched to risperidone long-acting injectable: A retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs", Int J Psychiatry Clin Pract, 14, pp.53~62 (2010)
59. Suzuki H, "The influence of switching from oral risperidone to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia", Ther Adv Psychopharmacol, 2, pp.23~29 (2012)
60. Suzuki H, "A study of the efficacy and safety of switching from oral risperidone to risperidone long-acting injection in older patients with schizophrenia", Ther Adv Psychopharmacol, 2, pp.227~234 (2012)
61. Weiden PJ, "A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients:initial adherence outcome", J Clin Psychiatry, 70, pp.1397~1406 (2009)
62. Weiden PJ, "Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia:a randomized effectiveness study", J Clin Psychiatry, 73, pp.1224~1233 (2012)
63. Willis M, "The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden", Eur J Health Econ, 11, pp.585~594 (2010)
64. Wykes T, "Working alliance and its relationship to outcomes in a randomized controlled trial (RCT) of antipsychotic medication", BMC Psychiatry, 13, pp.28~ (2013)
65. Andreasen NC, "Remission in schizophrenia: proposed criteria and rationale for consensus", Am J Psychiatry, 162, pp.441~449 (2005)
66. Martin CR, "Factor structure of the Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4)", Psychol Health Med, 12, pp.126~134 (2007)
67. Heinrichs DW, "The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome", Schizophr Bull, 10, pp.388~398 (1984)
68. Lambert T, "Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium", Ann Gen Psychiatry, 10, pp.10~ (2011)
69. Peng X, "Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia", Clinicoecon Outcomes Res, 3, pp.9~14 (2011)
70. Tiihonen J, "Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder:observational follow-up study", BMJ, 333, pp.224~ (2006)
71. Tiihonen J, "A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia", Am J Psychiatry, 168, pp.603~609 (2011)
72. Grimaldi-Bensouda L, "CGS Study Group. Does longacting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)", Schizophr Res, 134, pp.187~194 (2012)
73. Correll CU, "Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives", Dialogues Clin Neurosci, 13, pp.155~172 (2011)

관련 논문AI추천